NCT04557007 2026-01-29
Oncomabs
Oslo University Hospital
Terminated
Clinical Trials
3 trialsNCT05078931 2025-07-30
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT04164745 2019-11-15
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2 Unknown